RumaFeed

**Product and the concrete problem it solves.** RumaFeed is addressing a specific waste and food-security problem in potato and other Solanaceae production. Potato plants produce edible tubers, but their stems and leaves, known as haulm, contain steroidal glycoalkaloids such as solanine that can be toxic at elevated concentrations. Farmers commonly destroy the foliage before or around harvest, often with herbicides, because the biomass cannot safely enter conventional livestock-feed channels. That creates a double loss: water, labor, land, and crop inputs have been invested in biomass that is discarded, while livestock producers still need protein and feed. RumaFeed's proposed solution is to develop potato, tomato, capsicum, and eggplant varieties with materially lower or absent toxic glycoalkaloids in relevant plant parts. A successful trait would allow the foliage to be harvested, processed, and sold as an additional feed input rather than treated as waste. The value proposition is therefore not simply a new seed variety. It is a way to increase the useful output per hectare, create a second revenue stream for growers, reduce agricultural waste, lower herbicide use associated with foliage destruction, and improve the resilience of food and feed supply in regions with limited land or water. Public sources support the underlying problem and the low-glycoalkaloid approach, but they do not yet establish a commercially approved product or the full safety profile of every RumaFeed variety.

**Core technology and how it actually works.** RumaFeed's technical program combines plant physiology, genetics, trait development, and field validation. The public description is that the company genetically improves Solanaceae plants by reducing naturally occurring glycoalkaloids, while the disclosed patent application US20240381898A1 covers an edible composition or genetically modified Solanum plant or plant part devoid of steroidal glycoalkaloids and retaining dry-matter digestibility at least comparable to control plants. The patent record lists coverage or filings associated with Israel, China, Canada, and the United States, and the application was published in November 2024 with a pending status shown by IVC. That is meaningful intellectual-property evidence, but a published application is not an issued patent and does not prove freedom to operate, regulatory approval, or trait performance at scale. The technical workflow described in RumaFeed's investor material is appropriately long for a crop-trait company: molecular discovery, greenhouse confirmation, field validation, variety registration, and then commercial agreements. The deck estimates a total three-to-five-year cycle for a new crop or trait, with individual phases of roughly twelve to twenty-four months. The company also describes tissue-culture propagation and parallel work on potato and tomato traits. The key technical diligence question is whether lowering glycoalkaloids preserves agronomic performance, pest and disease resistance, yield, storage behavior, taste where relevant, and safe feed quality without creating new ecological or nutritional liabilities.

**Market, customers, and go-to-market.** RumaFeed is pursuing a B2B seed-trait and agricultural-biotechnology model rather than selling a consumer food product directly. Its likely customers are seed companies, variety owners, potato growers, processors, feed producers, and large agricultural organizations that can validate, multiply, distribute, or buy varieties carrying the trait. The company has described a model that can combine development fees for customer-specific varieties with royalties based on seeds sold or hectares planted. This structure is strategically sensible for a small company because it can monetize specialized trait development while using established seed and grower channels for distribution. RumaFeed's early market logic is also geographically selective: its presentation identifies North America as an initial focus and discusses later work in India and the United Kingdom, while public reporting documents field activity in southern Israel. Those are plans and signals, not evidence of completed commercial sales. The most concrete route to market visible in public sources is demonstration through controlled trials and partnerships. A potato trial was planned at Kibbutz Holit, an agricultural community near the Gaza border, and the company was selected to partner with Intel Ignite Tel Aviv. Before any broad rollout, it will need to show consistent trait expression across environments, obtain applicable food and feed approvals, persuade seed channels that the trait improves economics, and demonstrate that growers can harvest and process foliage without adding more cost than the recovered value.

**Traction, funding, and third-party validation.** RumaFeed has several credible early validation signals, although its operating scale remains small and public financial information is inconsistent. Calcalist reported in September 2025 that the company was founded in 2020, had four employees, and had raised $1.5 million. Startup Nation Finder separately lists two funding rounds, including pre-seed backing in 2022 from agricultural and university-linked participants and a 2025 strategic investment from Jewish National Fund-USA, while marking total amounts as undisclosed. The public record therefore supports seed or early R&D financing, but not a clean, independently reconciled cumulative funding total. The company also appears in Israeli innovation and entrepreneurship channels: it was included in Calcalist's Mind the Tech London 2025 Israeli startup delegation, and Times of Israel reported its partnership with Intel Ignite and planned trials at Holit. RumaFeed's investor deck records a provisional patent, a PCT submission, letters of intent in the United States, Canada, India, and the United Kingdom, and plans for large-scale field trials and commercial agreements. These deck items are company materials and should be verified directly; they should not be treated as executed contracts or revenue. The strongest external validation is the combination of a traceable Israeli corporate entity, a published patent application, named agricultural partners and trial locations, and repeated coverage by Israeli business and general-interest media. No reviewed source establishes current revenue, commercial seed sales, regulatory clearance, or repeat customer retention.

**Founders and team background.** RumaFeed was founded by Emeritus Professor Haim Rabinowitch, who is identified publicly as founder and CTO. Times of Israel describes him as a former rector of the Hebrew University of Jerusalem and dean of its Faculty of Agriculture, with expertise in plant physiology and genetics. The same report connects him to the team that developed commercial cherry tomatoes and long-shelf-life tomato varieties, an unusually relevant background for a company working on crop traits and the practical transition from academic breeding to agriculture. Public ecosystem records identify Oded Ilan as CEO and Itay Keren as Head of Agronomy and Operations. Ilan's professional profile describes prior leadership and business-development work in technology companies, while Keren's role indicates that the company is pairing scientific trait development with field and operational execution. The team size is reported differently by source: four employees in Calcalist, five in the Israel Innovation Authority ecosystem record, and eight in an IVC profile. A calibrated database value is therefore 4-8 rather than a single asserted count. The combination of a senior academic founder, an operator responsible for commercialization, and agronomy execution is directionally appropriate, but the organization is still very small for multi-country field trials, regulatory work, seed multiplication, and farmer support. Further diligence should identify the full scientific team, breeding and molecular-biology capabilities, regulatory advisers, and whether the founders have secured enough institutional capacity for the long validation cycle.

**Competitive dynamics and possible edge.** RumaFeed competes against several different approaches rather than one direct clone. Simplot's Innate potato program is an incumbent example of genetically improved potatoes developed for traits such as reduced bruising and reduced acrylamide, and demonstrates the distribution and regulatory advantages that large seed and food companies can bring. Pairwise and Tropic Biosciences represent newer gene-edited crop companies that compete for trait-development capital, regulatory attention, and grower adoption. Bayer and Syngenta compete through large-scale conventional breeding, biotechnology, crop-protection portfolios, and established relationships with seed channels. Conventional potato breeding and the existing feed market are also real substitutes: a grower can continue destroying haulm, buy alfalfa or other feed, or use non-gene-edited varieties while accepting lower resource efficiency. RumaFeed's possible edge is the coupling of a narrowly defined low-glycoalkaloid trait with a clear circular-economy monetization path. If the foliage can be safely converted into a valuable feed ingredient without sacrificing tuber yield or crop resilience, the trait could increase revenue from an existing field rather than require a new farm system. The edge is not proven. Large incumbents can reproduce or license traits, regulators may treat the product differently across jurisdictions, and the economics may fail if harvesting, drying, transport, testing, or feed formulation costs consume the recovered value.

**Defense, security, and resilience dual-use relevance.** RumaFeed's strategic relevance is centered on food security and agricultural resilience rather than a conventional military application. The core commercial product is a crop trait for growers and seed partners, while the same capability could strengthen resilience for communities, livestock systems, and national food supply chains exposed to drought, land scarcity, import disruption, conflict, or rising feed prices. Israel is particularly relevant as a proving environment because a significant share of its agricultural land and potato production lies near the Gaza border, where continuity of farming is a national resilience concern. The planned Holit trial also connects the technology to agricultural recovery in a conflict-affected community, although a trial is not proof of deployment or security impact. The strategic value comes from producing more usable food and feed from existing inputs, reducing dependence on imported feed, and making agricultural output less vulnerable to supply-chain shocks. There is no public evidence that RumaFeed supplies defense forces, supports military operations, or has a defense contract, and it should not be described as a defense technology company. The dual-use designation is therefore honest but asymmetric: commercial agricultural biotechnology on one side and civil food-security resilience on the other. Diligence should focus on biosafety, gene-flow controls, local regulation, farmer acceptance, and whether the trait remains beneficial under the pests, heat, water stress, and disrupted logistics that create the resilience case.

**Growth stage, trajectory, and key diligence risks.** RumaFeed is best classified as early stage and R&D, despite having operated since 2020 and receiving multiple forms of external support. The company has a specific patent position, public field-trial activity, an identified founding scientist, and a plausible royalty-based business model, but it remains dependent on years of agronomic validation, regulatory review, variety registration, seed-channel access, and farmer adoption. Its trajectory could be attractive if low-glycoalkaloid potatoes convert discarded biomass into a safe, standardized feed product and the same platform yields additional traits in tomatoes, peppers, or eggplant. The principal risks are: (1) technical risk that glycoalkaloid reduction affects plant defense, yield, storage, or food quality; (2) regulatory risk because gene-edited or genetically modified crops face different rules and timelines across target markets; (3) adoption risk if growers, processors, feed buyers, or consumers do not accept the trait or if harvesting haulm requires new equipment; (4) commercialization risk from relying on seed companies and long agricultural sales cycles; (5) financing risk because a very small team must fund multi-year field trials and regulatory work; (6) IP risk because a pending application is not an issued, enforceable patent portfolio; and (7) evidence risk because several milestones in the investor deck, including letters of intent and revenue forecasts, are not independently confirmed. The next proof points should be replicated field data, feed-safety results, regulatory decisions, signed commercial agreements, and evidence that farmers can realize positive net economics per hectare.